Profile data is unavailable for this security.
About the company
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
- Revenue in INR (TTM)34.54bn
- Net income in INR5.90bn
- Incorporated1924
- Employees3.68k
- LocationGlaxoSmithKline Pharmaceuticals LtdDr Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224959595
- Fax+91 2 224981526
- Websitehttps://india-pharma.gsk.com/en-in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd | 50.41bn | 1.61bn | 242.48bn | 5.75k | 151.48 | 5.90 | 43.86 | 4.81 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 260.53bn | 5.10k | 47.78 | 8.91 | 37.71 | 7.48 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Syngene International Ltd | 34.89bn | 5.10bn | 276.27bn | 6.85k | 54.29 | 6.48 | 29.52 | 7.92 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 289.98bn | 15.56k | -- | -- | -- | 2.47 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 302.46bn | 7.71k | 37.07 | 8.48 | 31.79 | 7.19 | 64.79 | 64.79 | 334.10 | 283.32 | 0.9034 | 1.30 | 3.65 | -- | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.51 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 15.18 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| Gland Pharma Ltd | 56.65bn | 7.72bn | 309.96bn | 4.59k | 40.13 | 3.55 | 27.75 | 5.47 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| IPCA Laboratories Ltd | 71.86bn | 5.64bn | 332.05bn | 16.17k | 58.83 | -- | 35.47 | 4.62 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
| Biocon Ltd | 147.56bn | 10.23bn | 377.59bn | 3.41k | 36.94 | 1.91 | 13.17 | 2.56 | 8.54 | 8.54 | 123.32 | 164.78 | 0.273 | 1.07 | 3.01 | -- | 2.40 | 3.20 | 3.50 | 4.48 | 66.81 | 63.27 | 8.80 | 9.37 | 0.6664 | 1.63 | 0.3917 | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| GlaxoSmithKline Pharmaceuticals Limited | 34.54bn | 5.90bn | 419.03bn | 3.68k | 71.02 | 23.57 | 63.52 | 12.13 | 34.83 | 34.83 | 203.92 | 104.93 | 1.00 | 2.71 | 16.67 | -- | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 56.53 | 17.08 | 12.25 | 1.49 | 466.12 | 0.0104 | 123.47 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 5.68m | 3.36% |
| Man Group Investments Ltd.as of 28 Feb 2023 | 2.48m | 1.46% |
| General Insurance Corp. of India (Invt Port)as of 30 Jun 2023 | 2.46m | 1.46% |
| Scottish Widows Ltd. (Investment Portfolio)as of 31 May 2021 | 1.94m | 1.15% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Apr 2024 | 1.66m | 0.98% |
| The Vanguard Group, Inc.as of 09 May 2024 | 1.60m | 0.94% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Apr 2024 | 1.56m | 0.92% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Apr 2024 | 1.47m | 0.87% |
| quant Money Managers Ltd.as of 30 Apr 2024 | 920.00k | 0.54% |
| SBI Funds Management Ltd.as of 30 Apr 2024 | 812.59k | 0.48% |
